Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

Pages

22 results
12:00 AM, Sep 07, 2015  |  BC Week In Review | Company News  |  Deals

RESprotect, RedHill deal

August 2014 deal granting it a one-year option to license exclusive, worldwide rights to RESprotect’s RP101
rights in South Korea to treat pancreatic cancer. In 2009, a Phase II trial of RP101
12:00 AM, Aug 03, 2015  |  BC Week In Review | Company News  |  Deals

Broda Tech, Redwood Pharma deal

worldwide rights to use IntelliGel supramolecular hydrogel technology for ophthalmic indications. Redwood has reformulated its RP101
12:00 AM, Sep 08, 2014  |  BC Week In Review | Company News  |  Deals

RESprotect, RedHill deal

RedHill received a one-year option from RESprotect to acquire exclusive, worldwide rights to RP101 for all …
development of the compound during the option period, which may be extended under agreed terms. RP101
Dong Pharmaceutical Co. Ltd. (KSE:009290, Seoul, South Korea) has exclusive rights to develop and commercialize RP101
12:00 AM, Jul 04, 2011  |  BC Week In Review | Company News  |  Deals

SciClone, RESprotect deal

RESprotect said SciClone returned North American rights to pancreatic cancer candidate RP101 . SciClone discontinued a …
an independent DSMC. RESprotect said the German regulatory authority approved an adapted development plan for RP101
12:00 AM, Nov 16, 2009  |  BC Week In Review | Clinical News  |  Regulatory

Brivudine regulatory update

Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for RESprotect's RP101
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), Foster City, Calif.   RESprotect GmbH , Dresden, Germany   Product: Brivudine
12:00 AM, Nov 02, 2009  |  BC Week In Review | Company News  |  Other News

SciClone cancer news

with cuts primarily in research and development. In October, SciClone discontinued a Phase II of RP101
to treat advanced pancreatic cancer based on the recommendation of an independent DSMC. RP101 is a …
12:00 AM, Oct 12, 2009  |  BC Week In Review | Clinical News  |  Clinical Results

BvdU: Phase II discontinued

and reviewed. The trial had completed enrollment of 153 patients to compare 6 cycles of RP101
plus Gemzar gemcitabine from Eli Lilly and Co. (NYSE:LLY) vs. Gemzar alone. RP101 has Orphan Drug …
adjunct to treat pancreatic cancer in the U.S. SciClone has U.S. and Canadian rights to RP101
12:00 AM, Apr 20, 2009  |  BC Week In Review | Company News  |  Deals

Acuvax, RESprotect deal

Acuvax said the deal would improve its cash position by over $750,000. RESprotect's pipeline includes RP101
Acuvax holds 27.2%. Avantogen Oncology Inc. (Pink:AVTO, Los Angeles, Calif.) has North American rights to RP101
subsidiary granted SciClone Pharmaceuticals Inc. (NASDAQ:SCLN, Foster City, Calif.) exclusive rights to develop and commercialize RP101
12:00 AM, Mar 16, 2009  |  BC Week In Review | Clinical News  |  Clinical Status

BVdU: Completed Phase II enrollment

of 153 patients in a double-blind, placebo-controlled, international Phase II trial comparing six cycles of RP101
plus gemcitabine vs. gemcitabine alone. RP101 has Orphan Drug designation to treat pancreatic cancer in the …
U.S. SciClone has U.S. and Canadian rights to RP101 from Avantogen Oncology, which has North American …
12:00 AM, Feb 11, 2008  |  BC Week In Review | Clinical News  |  Clinical Status

BVdU: Phase II started

Phase II trial in 153 patients to evaluate 6 cycles of gemcitabine with or without RP101
weeks followed by 1 week of rest. The company licensed U.S. and Canadian rights to RP101
Inc. (OTCBB:AVTO), Los Angeles, Calif.   SciClone Pharmaceuticals Inc. (NASDAQ:SCLN), San Mateo, Calif.   Product: BVdU

Pages